Literature DB >> 3542485

Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine.

B Tanrisever, P J Santella.   

Abstract

Cefadroxil is an oral cephalosporin which is similar to cephalexin and cephradine in structure and spectrum of antibacterial activity, but has different pharmacokinetic properties. Not only does cefadroxil exhibit a longer serum half-life, and thus a prolonged duration of activity, but it is virtually unaffected by simultaneous food intake. The concentrations of cefadroxil attained in body tissues and fluids are also higher and more sustained than those of cephalexin and cephradine. These characteristics permit the administration of cefadroxil during meals on a once-daily or twice-daily basis, thus encouraging patient compliance which often determines the successful management of out-patient infections. Many studies have established the efficacy of the administration of once- or twice-daily cefadroxil, compared with regimens of cephalexin or cephradine given 4 times daily, in the management of infections in the respiratory tract, urinary tract, skin and soft tissues, and bones and joints.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542485     DOI: 10.2165/00003495-198600323-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  66 in total

1.  Intraocular penetration of cephalexin in man.

Authors:  G L Boyle; H F Hein; I H Leopold
Journal:  Am J Ophthalmol       Date:  1970-05       Impact factor: 5.258

2.  An appraisal of cephalexin monohydrate levels in semen and prostatic tissue.

Authors:  J M Symes; J D Jarvis; G C Tresidder
Journal:  Chemotherapy       Date:  1974       Impact factor: 2.544

3.  Effect of experimentally induced renal impairment on the pharmacokinetics of cefadroxil in rabbits.

Authors:  E L Mariño; A A Dominguez-Gil; M Cepeda; M J Otero; A Dominguez-Gil
Journal:  Arzneimittelforschung       Date:  1981

4.  Comparative study of the penetration of penicillin V and cefadroxil into tonsils in man.

Authors:  S E Holm; C Ekedahl
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

5.  Oral cefadroxil in the treatment of bone and joint infections in children and adults.

Authors:  M Jimenez-Shehab; A Barragan
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

6.  Treatment of acute urinary tract infections with cefadroxil administered once daily.

Authors:  G Lewis
Journal:  J Int Med Res       Date:  1980       Impact factor: 1.671

7.  The role of cefadroxil in the therapy of urinary tract infections.

Authors:  R B Wilber; R G DeRegis; E J Fox
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

8.  Streptococcal pharyngitis therapy. Comparison of cephalexin, phenoxymethyl penicillin, and ampicillin.

Authors:  M Stillerman; H D Isenberg; M Moody
Journal:  Am J Dis Child       Date:  1972-05

9.  Amoxicillin, a new penicillin antibiotic.

Authors:  H H Handsfield; H Clark; J F Wallace; K K Holmes; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

10.  Antimicrobial therapy in infants and children: update 1976-1985. Part I.

Authors:  H F Eichenwald
Journal:  J Pediatr       Date:  1985-08       Impact factor: 4.406

View more
  9 in total

1.  In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2013-11       Impact factor: 4.200

2.  Population pharmacokinetic modeling of cefadroxil renal transport in wild-type and Pept2 knockout mice.

Authors:  Yehua Xie; Hong Shen; Yongjun Hu; Meihua Rose Feng; David E Smith
Journal:  Xenobiotica       Date:  2015-09-15       Impact factor: 1.908

3.  Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

4.  Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice.

Authors:  Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2016-03-12       Impact factor: 5.858

5.  Treatment of acute and chronic sinusitis with cefadroxil.

Authors:  I Kaminszczik
Journal:  Drugs       Date:  1986       Impact factor: 9.546

6.  A comparative study of cefadroxil and co-trimoxazole in patients with lower respiratory tract infections.

Authors:  M Castro
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.

Authors:  Yeamin Huh; Richard F Keep; David E Smith
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

8.  Physiologically Based Pharmacokinetic Modeling of Cefadroxil in Mouse, Rat, and Human to Predict Concentration-Time Profile at Infected Tissue.

Authors:  Zhongxia Tan; Youxi Zhang; Chao Wang; Le Sun
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

9.  Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections.

Authors:  Andrew S Haynes; Andrea Prinzi; Lori J Silveira; Sarah K Parker; Jed N Lampe; Jeffrey S Kavanaugh; Alexander R Horswill; Douglas Fish
Journal:  Microbiol Spectr       Date:  2022-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.